•
Mar 31, 2022
Protalix Q1 2022 Earnings Report
Protalix reported an increase in revenue and a reduced net loss compared to the same period last year.
Key Takeaways
Protalix BioTherapeutics reported a strong first quarter with a 100% increase in revenue from selling goods and a significant reduction in net loss. Positive clinical trial results for PRX-102 and regulatory advancements in Europe highlight the company's progress in treating Fabry disease.
Revenues from selling goods increased by 100% to $9.0 million compared to Q1 2021.
Revenue from licenses and R&D services increased slightly to $7.1 million.
Net loss decreased to $2.3 million, or $0.05 per share, compared to a net loss of $5.5 million, or $0.14 per share, in Q1 2021.
Positive results from Phase III clinical trials for PRX-102 were announced, supporting BLA resubmission to the FDA.
Protalix
Protalix
Forward Guidance
The company did not provide forward guidance in this report.